论文部分内容阅读
目的 :观察硒治疗桥本氏甲状腺炎的临床疗效。方法 :将已用左旋甲状腺素治疗 3月甲状腺未明显缩小 ,甲状腺球蛋白抗体 (TGA)、微粒体抗体 (MCA)仍未明显降低的桥本氏病患者随机分成补硒组 (4 2例 )、对照组 (3 0例 )。 3月后对两组患者甲状腺大小及TGA、MCA测定。结果 :补硒组 3 0人 (71 4% )甲状腺明显缩小 ,TGA2 8人 (66 6% )、MCA2 5人 (5 9 5 % )明显降低 ,差异有显著性。结论 :甲状腺激素治疗基础上补硒治疗对桥本氏病患者甲状腺缩小及自身抗体水平降低是有益的。
Objective: To observe the clinical efficacy of selenium in treating Hashimoto’s thyroiditis. Methods: Patients with Hashimoto’s disease who had not been significantly reduced thyroid with levothyroxine for 3 months and whose thyroglobulin antibody (TGA) and microsomal antibody (MCA) had not yet been significantly reduced were randomly divided into selenium-supplemented group (42 cases) , Control group (30 cases). Thyroid size, TGA and MCA were measured in two groups after 3 months. Results Thirty thyroid glands were significantly reduced in 30 patients (71.4%) in selenium group, 8 (66.6%) in TGA2 and 5 5 (5 59%) in MCA2 were significantly decreased. CONCLUSIONS: Selenium supplementation, on the basis of thyroid hormone therapy, is beneficial for patients with Hashimoto’s disease to have thyroid shrinkage and decreased levels of autoantibodies.